Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13430583 | 0.91 | — | — | |
| SCHEMBL7303932 | 0.80 | ALDH1A1 (0.40) | RAB9APKMNPC1TP53POLB | |
| SCHEMBL7302610 | 0.80 | CLK4 (0.44) | PKMCA2POLBLMNAHTT | |
| SCHEMBL7297774 | 0.79 | FYN (0.39) | KDM4ELMNASMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL7293097 | 0.79 | STK10 (0.40) | STK10SLKCYP3A4 | |
| SCHEMBL629944 | 0.79 | HSD11B1 (0.43) | RAB9APKMHSD11B1L3MBTL1POLB | |
| SCHEMBL7444756 | 0.78 | FYN (0.39) | KDM4EHTTSMN1; SMN2STK10SLK | |
| SCHEMBL7303598 | 0.77 | CA12 (0.35) | RAB9ATP53CA12CA1CA2 | |
| SCHEMBL7293888 | 0.77 | CA12 (0.35) | RAB9AHSD11B1CA12CA1CA2 | |
| SCHEMBL7296783 | 0.76 | DDB1 (0.37) | PKMCA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119823052-A | Preparation method of bosentan | 致卓医药科技(北京)有限责任公司 | 2025-04-15 | — | — | CN | claimed |
| CN-114907275-A | Preparation method of bosentan | 武汉工程大学 | 2022-08-16 | — | — | CN | claimed |
| CN-119823052-B | Preparation method of bosentan | 致卓医药科技(北京)有限责任公司 | 2025-11-25 | — | — | CN | disclosed |
| CN-119823052-A | Preparation method of bosentan | 致卓医药科技(北京)有限责任公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119823052-A | Preparation method of bosentan | 致卓医药科技(北京)有限责任公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-114907275-A | Preparation method of bosentan | 武汉工程大学 | 2022-08-16 | — | — | CN | disclosed |
| EP-2603497-B1 | A NOVEL PROCESS FOR PREPARATION OF BOSENTAN | MEGAFINE PHARMA P LTD (IN) | 2018-08-08 | — | — | EP | disclosed |
| US-9139537-B2 | Process for preparation of bosentan | MEGAFINE PHARMA(P) LTD. (IN) | 2015-09-22 | — | — | US | disclosed |
| US-20130296560-A1 | Novel Process For Preparation Of Bosentan | MEGAFINE PHARMA (P) LTD. (IN) | 2013-11-07 | — | — | US | disclosed |
| EP-2603497-A1 | A NOVEL PROCESS FOR PREPARATION OF BOSENTAN | Megafine Pharma (P) Ltd. (IN) | 2013-06-19 | — | — | EP | disclosed |
| US-20120136015-A1 | PROCESS FOR PREPARATION OF ENDOTHELIAL RECEPTOR ANTAGONIST (BOSENTAN) | SANDOZ AG (CH) | 2012-05-31 | — | — | US | disclosed |
| WO-2009093127-A2 | SUBSTANTIALLY PURE AND A STABLE CRYSTALLINE FORM OF BOSENTAN | ACTAVIS GROUP PTC EHF (IS) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009047637-A1 | NOVEL POLYMORPHS OF BOSENTAN | ACTAVIS GROUP PTC EHF (IS) | 2009-04-16 | — | — | WO | disclosed |
| US-20090069351-A1 | DEUTERIUM-ENRICHED BOSENTAN | PROTIA, LLC (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069351-A1 | DEUTERIUM-ENRICHED BOSENTAN | PROTIA, LLC (US) | 2009-03-12 | — | — | US | disclosed |
| WO-2008122020-A1 | SUBSTITUTED PYRIMIDINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008122020-A1 | SUBSTITUTED PYRIMIDINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| US-20080242687-A1 | SUBSTITUTED PYRIMIDINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080242687-A1 | SUBSTITUTED PYRIMIDINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080242687-A1 | SUBSTITUTED PYRIMIDINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069351-A1 | DEUTERIUM-ENRICHED BOSENTAN | AVPR2, BDKRB2, AVPR1B | RAB9A 2358/4885PKM 3361/4885NPC1 2506/4885 |
| US-20080242687-A1 | SUBSTITUTED PYRIMIDINES | EDNRB, EDNRA, ECE1 | RAB9A 4007/4885PKM 1104/4885NPC1 2006/4885 |
| US-20120136015-A1 | PROCESS FOR PREPARATION OF ENDOTHELIAL RECEPTOR ANTAGONIST (BOSENTAN) | EDNRA, EDNRB, TBXA2R | RAB9A 3942/4885PKM 2501/4885NPC1 4632/4885 |
| US-20130296560-A1 | Novel Process For Preparation Of Bosentan | BMP6, EDNRB, PAH | RAB9A 1246/4885PKM 2609/4885NPC1 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.